Guidance Notes

International Tax

GNT 35: Tax Implications of Brexit on the Pharmaceutical Industry

International Tax

GNT 33: Diverted Profits Tax

International Tax

GNT 32: Setting up in the US

International Tax

GNT 26: BEPS Overview

International Tax

GNT 24: Intercompany Agreements for Transfer Pricing

International Tax

GNT 23: Permanent Establishments

International Tax

GNT 14: Benefits of Incorporating in the UK

International Tax

GNT 13: Expansion into New Territories

International Tax

GNT 12: UK the Case for Inward Investment

International Tax

GNT 11: Transfer Pricing Essentials

Transactions

GNT 50: Retention of Losses Post Merger

Transactions

GNT 39: Demergers

Transactions

GNT 21: Tax Efficient Divestment

Transactions

GNT 20: Substantial Shareholdings Exemption

Transactions

GNT 4: Deferred Consideration

Transactions

GNT 3: Licensing

NEW Tax Compliance

GNT 42: Corporation Tax Loss Relief Reform

Tax Compliance

GNT 38: Bioscience Explained to Support Tax Returns

Tax Compliance

GNT 29: Tax Model

Tax Compliance

N-Site

GNT 35: Tax Implications of Brexit on the Pharmaceutical Industry

GNT 33: Diverted Profits Tax

GNT 32: Setting up in the US

GNT 26: BEPS Overview

GNT 24: Intercompany Agreements for Transfer Pricing

GNT 23: Permanent Establishments

GNT 14: Benefits of Incorporating in the UK

GNT 13: Expansion into New Territories

GNT 12: UK the Case for Inward Investment

GNT 11: Transfer Pricing Essentials

GNT 50: Retention of Losses Post Merger

GNT 39: Demergers

GNT 21: Tax Efficient Divestment

GNT 20: Substantial Shareholdings Exemption

GNT 4: Deferred Consideration

GNT 3: Licensing

GNT 42: Corporation Tax Loss Relief Reform

GNT 38: Bioscience Explained to Support Tax Returns

GNT 29: Tax Model

GNT 17: Compliance Essentials